For citations:
Zamergrad MV, Parfenov VA, Agafina AS, Lyamina NV, Gavrik MM, Kuchumova LR, Barantsevich ER, Krasnov VS, Ivanova AA, Vladykin AL, Ishchenko KА. Efficacy and safety of Vespireit® (buspirone) prolonged-release tablets (PR) 15 mg in the therapy of patients with functional dizziness: results of the double-blind, placebo-controlled, multicenter, randomized, phase 3 clinical trial. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2023;15(5):20-34. (In Russ.) https://doi.org/10.14412/2074-2711-2023-5-20-34
Email this article 